Letter to CMS Requesting That Blood-Derived Products HCPCS Code G0465 Be Considered Under Potentially Misvalued Code Process
Summary: Advocacy letter from wound care stakeholders to CMS requests review of HCPCS code G0465 (blood-derived products for wound care) under the potentially misvalued code process. Argues current valuation outdated, undervalues products (e.g., PRP, autologous blood derivatives), limits access/innovation, and hinders chronic wound management (DFUs, VLUs). Cites evidence: High costs, clinical benefits (healing acceleration), need for accurate reimbursement to support evidence-based use. Seeks revaluation for fair payment, reduced barriers, and improved outcomes in advanced therapies. Part of broader efforts for sustainable coverage.
Keywords: HCPCS G0465, blood-derived products, CMS misvalued, wound care advocacy